Uptake and safety of Sotrovimab for prevention of severe COVID-19 in a cohort and self-controlled case series study
Background: Sotrovimab is a neutralising monoclonal antibody (nMAB) currently available to treat extremely clinically vulnerable COVID-19 patients in England. Trials have shown it to have mild to moderate side effects, however, evidence regarding its safety in real-world settings remains insufficien...
Main Authors: | Patone, M, Snelling, AJ, Tibble, H, Coupland, C, Sheikh, A, Hippisley-Cox, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Nature Research
2025
|
Similar Items
-
Effectiveness and safety of COVID-19 vaccination in people with blood cancer
by: Copland, E, et al.
Published: (2024) -
Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England
by: Copland, E, et al.
Published: (2024) -
External validation of the QCovid 2 and 3 risk prediction algorithms for risk of COVID-19 hospitalisation and mortality in adults: a national cohort study in Scotland
by: Kerr, S, et al.
Published: (2023) -
Real-world effectiveness of sotrovimab and remdesivir for early treatment of high-risk hospitalized COVID-19 patients: a propensity score adjusted retrospective cohort study
by: Koh, Lin Pin, et al.
Published: (2023) -
An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: a national validation cohort study in England
by: Nafilyan, V, et al.
Published: (2021)